Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein

Journal of Virology

Volumn 76, Issue 8, 2002, Pages 3800-3809

  Silvera, Peter ^a   Richardson, Max W ^a   Greenhouse, Jack ^a   Yalley Ogunro, Jake ^a   Shaw, Nigel ^a   Mirchandani, Jyotika ^a   Khalili, Kamel ^a   Zagury, Jean Francois ^a   Lewis, Mark G ^a   Rappaport, Jay ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; NEF PROTEIN; REV PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TAT TOXOID; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION PREVENTION; LYMPHOCYTE COUNT; NONHUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROVOCATION TEST; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VACCINATION; VACCINE PRODUCTION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS STRAIN;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; LYMPHOCYTES; MACACA MULATTA; MOLECULAR SEQUENCE DATA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VACCINATION;

EID: 0036193785     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.8.3800-3809.2002     Document Type: Article

References (36)

1. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals
2. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
3. AIDS vaccine development in primate models
4. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III)
5. Control of SHIV-89.6P infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
6. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine
7. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P)
8. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge
9. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication
10. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine
11. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients
12. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation
13. HIV-1 Tat protein as a potential AIDS vaccine
14. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains
15. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33)
16. Tat toxoid as a component of a preventive vaccine in seronegative subjects
17. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients
18. Molecular cloning of SIV from sooty mangabey monkeys
19. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains
20. HIV type 1 Tat protein enhances activation but not Fas (CD95)-induced peripheral blood T cell apoptosis in healthy individuals
21. Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus
22. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein
23. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection
24. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
25. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo
26. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
27. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
28. Contribution of antibody response to recombinant HIV-1 gene-encoded products Nef, Rev, Tat, and protease in predicting development of AIDS in HIV-1-infected individuals
29. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
30. Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat
31. Antibody to HIV-1 Tat protein inhibits the replication of virus in culture
32. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness
33. Plasma SIV RNA viral load determination by real-time quantitation of product generation in reverse transcriptase-polymerase chain reaction
34. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1
35. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS
36. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine